ISSN: 1859 - 2872
Long-term survival in patients with early-stage non-small cell lung cancer treated by stereotactic body radiation therapy
Main Article Content
Keywords
Abstract
Background: Stereotactic body radiotherapy (SBRT) is indicated for the treatment of patients with early-stage non-small cell lung cancer (NSCLC) who are not candidates for surgery and has been initially applied in Vietnam. The objective of this study is to evaluate the long-term survival rate after SBRT in patients with stage I NSCLC (T1-T2aN0M0) who are not candidates for surgery. Subejct and method: Prospective study, longitudinal follow-up of 32 patients with stage T1-T2aN0M0 NSCLC, classified according to AJCC version 7.2010, peripheral lung tumors, who received SBRT from January 2015 to November 2021 and then they were followed and evaluated until November 2024. The main criteria were overall survival (OS), survival rates of 3 years, 4 years, and 5 years. Secondary endpoints were update of progression-free survival (PFS) and adverse events. Result: Median PFS was 26 months, 2-year PFS was 53.1%, 3-year PFS was 43.8%, and 4-year PFS was 36.3%. Median OS was 68 months, estimated OS at 3 years was 81.3%, 4-year OS was 64.4%, and 5-year OS was 51%. Patients with a SUVmax value pre-SBRT > 5 had a progression rate of 76.9%, which was statistically significantly higher than patients with SUVmax ≤ 5 at 16.7%, p= 0.005. No additional patients experienced late adverse events. Conclusion: SBRT is a radical treatment that provides good long-term survival and is safe for patients with early-stage NSCLC with peripheral lung tumors inoperable.
Article Details
References
2. Donington J, Ferguson M, Mazzone P et al (2012) American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for evaluation and management for high-risk patients with stage I Non-small cell lung cancer. Chest 142(6): 1620-1635.
3. Schneider BJ, Daly ME, Kennedy EB et al (2017) Stereotactic Body Radiation Therapy for Early-stage non-small cell lung cancer: American Society for Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol 36: 710-719.
4. Shinde A, Li R, Kim J et al (2018) Stereotactic Body Radiation Therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology 45: 210-219.
5. Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Carcinoma: Four-Year Results of a Prospective Phase II Study. Int J Radiat Oncol Biol Phys 75(3): 677-82.
6. Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7): 1623-31.
7. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic Body Radiation Therapy for Inoperable Early-Stage Lung Cancer. JAMA 303(11): 1070-6.
8. Nagata Y, Hiraoka M, Shibata T et al (2012) Stereotactic Body Radiation Therapy for T1N0M0 Non-small Cell Lung Cancer First Report for Inoperable Population of a Phase II Trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys 84(Suppl): 46-46.
9. Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Results of a prospective trial. Lung cancer 68(1): 72-77.
10. Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a Prospective Phage II Trial of Medically Inoperable stage I non-small cell lung cancer patients treated with Stereotactic Body Radiation Therapy. J Clin Oncol 27: 3290-3296.
11. Chang JY, Mehran RJ, Lei Feng et al (2021) Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial. Journal of Clinical Oncology. 39(15) Abstract 8056. DOI: 10.1200/JCO.2021.39.15.
12. Pham Van Luan, Nguyen Đinh Tien Le Ngoc Ha et al (2022) The result of treatment for early-stage non-small cell lung cancer patients by stereotactic body radiation therapy. Journal of 108-clinical medicine and pharmacy 17(5): 28-38.
13. Timmerman RD, Hu C, Michalski JM et al (2018) Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol S 4(9):1287-1288. doi: 10.1001/jamaoncol.2018.1258.
14. Chang JY, Suresh Senan, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol 16(6): 630-637.
15. Senthi S, Lagerwaard FJ, Haasbeek CJ et al (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis. J Thorac Oncol 7(11): 1858-1864. doi: 10.1097/JTO.0b013e31826bb7c1.
16. Huang K, Senthi S, Palma DA et al (2014) High-risk clinical and pathologic features for early distant metastasis after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 88(2): 368-374. doi: 10.1016/j.ijrobp.2013.10.033.
17. Takeda A, Sanuki N, Tsurugai Y et al (2011) Maximum standardized uptake value on FDG-PET predicts distant metastasis in stage I non-small-cell lung cancer after stereotactic body radiotherapy. Radiother Oncol 101(2): 291-297. doi: 10.1016/j.radonc.2011.08.033.
18. Thibault I, Chiang A, Erler D et al (2016) Predictors of Chest Wall Toxicity after Lung Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol) 28: 28-35.
Article Sidebar
